Business
Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical
Prominent Biotech Investor Gene Salkind Adds Another $2M Investment in CURE Pharmaceutical.
About this update from Avenir Wellness Solutions Inc.
[{"type":"text","content":"\nOXNARD, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, has announced that the company secured a $2 million investment at $2.5 per share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 million. In February 2018, Dr. Salkind joined CURE’s advisory board to help advance CURE’s pipeline for the central nervous system and other therapeutic areas.\n “This second round of financing from Dr. Salkind is an example of the confidence our investors see in the company’s future,” said Robert Davidson, CEO and Chairman of the Board of CURE Pharmaceutical. “His support and counsel have been and will continue to be instrumental in guiding our growth strategy.” Dr. Salkind is a prominent investor in the pharmaceutical arena. Past previous successful investments include Intuitive Surgical, Pharmacyclics, which grew from less than $1 per share to subsequently being acquired by Abbvie for $250/share, and Centocor, one of the nation's largest biotechnology companies, which was acquired by Johnson & Johnson for $4.9 billion in stock. Dr. Salkind currently sits on the board of DermTech, a private company based in San Diego that has become the global leader in non-invasive dermatological molecular diagnostics. “In the past year, CURE has evolved as a leader in the biotechnology field through its continual pursuit of redefining traditional drug delivery,” said Dr. Salkind. “We want to continue this momentum and pave the way for more partnerships and product offerings that will transform the medical field in association with CURE. About CURE PharmaceuticalsCURE Pharmaceutical is a fully integrated drug delivery and development committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to adva...